Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination ...
Introduction Sodium-glucose cotransporter (SGLT) inhibitors have shown substantial benefit in reducing cardiovascular and kidney events across diverse clinical populations, but the underlying ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...
Early-phase clinical trials involving PIM-1 kinase inhibitors look promising. In the evolving landscape of myelofibrosis (MF) ...
Findings from a phase 1/2 trial (NCT04176) presented at the 2025 American Society of Hematology Annual Meeting and Exposition ...
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in ...
Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting ...
Zongertinib gained accelerated approval for unresectable/metastatic HER2 kinase-domain–mutant nonsquamous NSCLC, with 76% ORR and DOR ≥12 months in 44%. AMPLIFY ...
The ATTC platform integrates monoclonal antibodies with small-molecule inhibitor payloads to provide dual mechanisms of ...
Researchers from the University of Seville have participated in research to identify the molecular details of the regulation of an enzyme essential for sugar metabolism and closely linked to cell ...
Nutritional status of patients undergoing cancer treatment has been associated with cancer therapy and survival outcomes across multiple therapy types. Targeted therapies, including immune checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results